WeVote
Log In

Bill

Bill

SB 1548

Relating to marijuana; prescribing an effective date.

2026 Regular Session

Imposes strict packaging, labeling, serving-size, and health-warning requirements for cannabis and hemp products to protect minors and inform consumers.

In committee upon adjournment.
0
WeVote Research Nonpartisan
Bill Summary · SB 1548

Summary of Senate Bill 1548 (2026 Regular Session, Oregon)

This summary outlines the main purpose, key provisions, affected parties, and notable procedural/timeline aspects of SB 1548 as introduced and in its amended form.

Purpose and Intent

  • The bill tightens regulation around cannabis and cannabinoid products in Oregon, with a strong focus on protecting minors, informing consumers about health risks, and standardizing labeling, packaging, and serving size rules.
  • It introduces requirements for single-unit packaging, explicit health warnings, and limits on serving sizes and total cannabinoid content per package.
  • The measure also authorizes local governments to establish buffer zones around cannabis and medical marijuana facilities and sets labeling and education requirements for products containing industrial hemp-derived cannabinoids.

Key Provisions

Packaging, Labeling, and Health Information

  • Marijuana items and inhalant delivery systems containing industrial hemp-derived cannabinoids must carry health information labels or inserts (Section 2 and Section 6-7).
  • Labels/ Inserts must include:
    • Recommendations to start with lower doses for new consumers.
    • Warnings about delayed onset of cannabinoids from edibles (up to four hours; cautions about proceeding within the window).
    • Dangers of illegal hemp-derived products (unregulated testing, potential contaminants).
    • Warnings about use during pregnancy/breastfeeding and risks to fetal development.
    • Information on mental health risks (psychotic disorders, suicidality) with emphasis on higher risk for frequent users and higher-THC products.
    • The link between higher THC content and adverse effects/impairment.
    • Legal prohibition of driving under the influence of cannabinoids and increased crash risk.
    • Associations between early/ frequent use and potential harm to developing brains.
    • Potential for cannabis inhalants to worsen breathing problems and risk of nausea/vomiting with prolonged use.
  • If a product’s packaging is too small for a label, a pamphlet/insert must be provided to consumers (Section 2).
  • Packages may include a pamphlet or insert, and retailers must provide it at point of sale (Section 2).

Cannabinoid Edibles and Concentrates

  • All cannabinoid edibles must be individually wrapped; for cannabinoid edibles that are not potable liquids, each piece must be wrapped (Section 7).
  • A single serving for adult-use cannabinoid products may include up to 10 milligrams of adult-use cannabinoids (per individual edible) and up to 100 milligrams per package for total THC/cannabinoids (Section 8).
  • Rules allow different labeling/packaging standards for different product varieties and require cost considerations and environmental impacts to be weighed (Section 6-7).

Serving Size and Concentration Limits

  • Maximum concentrations per single serving and per package are regulated, with distinctions for adult-use consumers and medical registry holders (Section 8).
    • Per-package limit: up to 100 milligrams of adult-use cannabinoid per edible package.
    • Per-edible limit: up to 10 milligrams of adult-use cannabinoid per individual edible.
    • The rules must consider the needs of medical-utility for registry holders (Section 8).

Local Regulation and Buffer Zones

  • Local governments may establish buffer zones greater than 1,000 feet around adult-use cannabis and medical marijuana operations in the interest of public health and safety (Section 5).

Administration and Operation

  • The Oregon Liquor and Cannabis Commission (OLCC) is required to adopt and enforce the new labeling, packaging, and safety standards, in coordination with the Oregon Health Authority and the State Department of Agriculture (Sections 2, 6, 7, 8, 9, 12).
  • The Act also clarifies OLCC’s authority to regulate advertising to protect minors and public health, including prohibiting misleading or unsafe marketing practices (Section 4).

Effective Dates

  • Key provisions become operative on different dates:
    • Section 3 (usable cannabis cannot be infused with additional cannabinoids) takes effect January 1, 2027.
    • Section 2 (labeling for hemp-derived cannabinoids) becomes operative July 1, 2027.
    • Other packaging/labeling standards and concentration rules generally become effective January 1, 2027 for certain products; final alignment and related rules span into 2027-2028 depending on amendments (Section 10-11).
  • The act as a whole takes effect 91 days after adjournment sine die of the 2026 session (Section 12).

Who Is Affected

  • OLCC: Must adopt and enforce expanded labeling, packaging, and advertising rules.
  • Oregon Health Authority and State Department of Agriculture: Coordinate with OLCC on health and agricultural considerations for labeling and product standards (ongoing).
  • Cannabis producers, processors, wholesalers, and retailers: Must comply with new packaging, labeling, serving-size, and concentration standards; may face new license/permit considerations and related fees (Sections 4, 5, 6, 7, 8).
  • Medical marijuana program participants: Subject to aligned concentration standards for transfers from medical dispensaries (Section 8 and related references to medical transfers).
  • Local governments: Granted authority to implement buffer zones around cannabis and hemp-derived cannabinoid operations (Section 5).

Procedural and Timeline Notes

  • The bill sets a phased implementation:
    • Early administrative actions possible prior to the operative dates.
    • Primary labeling/packaging changes involve a July 1, 2027 effective date for certain hemp-derived labeling rules.
    • Broader cannabinoid product concentration and packaging changes apply to products sold after January 1, 2027 (with some provisions referencing 2028 in amendments).
  • There are proposed amendments (SB 1548-A2) that adjust specific dates from 2027 to 2028, indicating potential changes during negotiations.

Bottom Line

SB 1548 advances comprehensive consumer-safety measures for cannabis and hemp-derived cannabinoids, emphasizing:
- Single-unit packaging and strict serving-size limits,
- Clear health risk labeling/inserts to inform buyers,
- Protection of minors through packaging design and advertising standards,
- Local control to create buffer zones for public health and safety,
- A staged implementation with multiple operative dates through 2027–2028.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.